Kodai Kawamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kodai Kawamura has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Kazuya Ichikado
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan
19 shared publicationsMoritaka Suga
Division of Respiratory Medicine, Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc., Saiseikai Kumamoto Hospital, Minami-ku, Kumamoto, Japan
11 shared publications- Keisuke Anan
Department of Healthcare Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
9 shared publications - Yoshihiko Sakata
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto 861-4193, Japan
9 shared publications Masakazu Yoshioka
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan
7 shared publicationsYuko Yasuda
Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan
7 shared publications
Latest Publications
- 7 October 2026
- Published by Wiley in Respirology
Predictive Model for Identifying Fibrotic Interstitial Lung Abnormalities on Computed Tomography for Respiratory Specialists
Background and Objective: Interstitial lung abnormalities (ILAs) are often unreported, and fibrotic ILAs carry a worse prognosis. In this study, we aimed to develop and validate a prediction model for fibrotic ILAs using non‐radiological factors. Methods: Using data from the Kumamoto ILA study (a multicenter prospective cohort in Japan), we developed a four‐variable model (age, pack‐years, fine crackles, elevated serum surfactant protein‐D) in 164 patients (2022–2023, derivation cohort) and temporally validated it in 207 patients (2023–2024, validation cohort), with internal‐external cross‐validation for between‐center heterogeneity. A simplified integer score was similarly assessed against 24‐month functional decline and treatment initiation within 3 years. Results: Fibrotic ILAs comprised 82% of cases (approximately 60% subsequently met ATS‐defined ILD criteria), consistent across cohorts. The four‐variable model achieved an AUC of 0.79 (derivation) and 0.76 (validation; pooled 0.76, 95% CI 0.68–0.82), with good calibration and minimal between‐center heterogeneity. The integer score performed similarly (AUC 0.79/0.75) and correlated with functional decline (%FVC ≥ 10% or %DLco ≥ 15%) and treatment initiation. Conclusion: Age, smoking exposure, fine crackles, and elevated serum surfactant protein‐D are key predictors of progressive fibrotic ILAs, supporting early risk stratification and clinical decision‐making. Trial Registration: UMIN000045149/2021.12.1
- 7 October 2026
- Published by Wiley in Respirology
Predictive Model for Identifying Fibrotic Interstitial Lung Abnormalities on Computed Tomography for Respiratory Specialists
Background and Objective: Interstitial lung abnormalities (ILAs) are often unreported, and fibrotic ILAs carry a worse prognosis. In this study, we aimed to develop and validate a prediction model for fibrotic ILAs using non‐radiological factors. Methods: Using data from the Kumamoto ILA study (a multicenter prospective cohort in Japan), we developed a four‐variable model (age, pack‐years, fine crackles, elevated serum surfactant protein‐D) in 164 patients (2022–2023, derivation cohort) and temporally validated it in 207 patients (2023–2024, validation cohort), with internal‐external cross‐validation for between‐center heterogeneity. A simplified integer score was similarly assessed against 24‐month functional decline and treatment initiation within 3 years. Results: Fibrotic ILAs comprised 82% of cases (approximately 60% subsequently met ATS‐defined ILD criteria), consistent across cohorts. The four‐variable model achieved an AUC of 0.79 (derivation) and 0.76 (validation; pooled 0.76, 95% CI 0.68–0.82), with good calibration and minimal between‐center heterogeneity. The integer score performed similarly (AUC 0.79/0.75) and correlated with functional decline (%FVC ≥ 10% or %DLco ≥ 15%) and treatment initiation. Conclusion: Age, smoking exposure, fine crackles, and elevated serum surfactant protein‐D are key predictors of progressive fibrotic ILAs, supporting early risk stratification and clinical decision‐making. Trial Registration: UMIN000045149/2021.12.1
- 30 June 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (8) , 103023
Comprehensive risk assessment and evaluation of the impact of amino acid preparations on peripheral line-associated bloodstream infection: A single-center retrospective observational study using propensity score matching
- 30 June 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (8) , 103023
Comprehensive risk assessment and evaluation of the impact of amino acid preparations on peripheral line-associated bloodstream infection: A single-center retrospective observational study using propensity score matching
- Open Access
- 3 June 2026
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 62, 102444
Successful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer
- 3 June 2026
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 62, 102444
Open AccessSuccessful Re-challenge of zongertinib following erythema multiforme-like drug eruption in a patient with HER2-mutant non-small cell lung cancer
- Open Access
- 18 December 2025
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 218-223
Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report
Introduction: Tarlatamab is a bispecific T-cell engager (BiTE) targeting DLL3 and shows promising efficacy in relapsed small cell lung cancer (SCLC). Although flare reactions are recognized with immune checkpoint inhibitors, reports in patients receiving tarlatamab remain limited. Case Presentation: We describe the case of a 74-year-old woman with extensive-stage SCLC who developed acute radiological worsening within 4 days after initiating third-line tarlatamab therapy, followed by rapid improvement by day 8. Chest computed tomography performed 1 week prior to treatment and on day 1 revealed no significant changes in the right hilar mass size (56.5 mm vs. 54.0 mm) or the right lower lobe infiltrating shadow (82.5 mm vs. 82.0 mm). On day 4, the right hilar mass and lower lobe lesion increased to 68.0 mm and 74.1 mm, respectively, along with surrounding ground-glass opacity and pleural effusion. By day 8, these lesions had decreased to 56.3 mm and 73.8 mm, respectively, and were further reduced by day 15 to 54.1 mm and 73.3 mm, respectively, with complete resolution of pleural effusion. Cytokine release syndrome (grade 1–2) was noted with tarlatamab administration on days 1, 8, and 15. Based on the temporal association, imaging findings, and clinical course, the event was considered flare reaction rather than natural tumor progression. Conclusion: Our findings suggest that flare reaction occurs within days of initiating tarlatamab, possibly attributable to acute immune activation, as reported in BiTE therapies. Awareness of this possibility may help avoid premature discontinuation of effective treatment.
- 18 December 2025
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 218-223
Open AccessFlare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report
Introduction: Tarlatamab is a bispecific T-cell engager (BiTE) targeting DLL3 and shows promising efficacy in relapsed small cell lung cancer (SCLC). Although flare reactions are recognized with immune checkpoint inhibitors, reports in patients receiving tarlatamab remain limited. Case Presentation: We describe the case of a 74-year-old woman with extensive-stage SCLC who developed acute radiological worsening within 4 days after initiating third-line tarlatamab therapy, followed by rapid improvement by day 8. Chest computed tomography performed 1 week prior to treatment and on day 1 revealed no significant changes in the right hilar mass size (56.5 mm vs. 54.0 mm) or the right lower lobe infiltrating shadow (82.5 mm vs. 82.0 mm). On day 4, the right hilar mass and lower lobe lesion increased to 68.0 mm and 74.1 mm, respectively, along with surrounding ground-glass opacity and pleural effusion. By day 8, these lesions had decreased to 56.3 mm and 73.8 mm, respectively, and were further reduced by day 15 to 54.1 mm and 73.3 mm, respectively, with complete resolution of pleural effusion. Cytokine release syndrome (grade 1–2) was noted with tarlatamab administration on days 1, 8, and 15. Based on the temporal association, imaging findings, and clinical course, the event was considered flare reaction rather than natural tumor progression. Conclusion: Our findings suggest that flare reaction occurs within days of initiating tarlatamab, possibly attributable to acute immune activation, as reported in BiTE therapies. Awareness of this possibility may help avoid premature discontinuation of effective treatment.
- Open Access
- 8 March 2025
- Published by Elsevier in Regenerative Therapy
- Vol. 29, 35-42
Clinical efficacy of invimestrocel for acute respiratory distress syndrome caused by pneumonia: Comparison with historical data using propensity score analysis
- 8 March 2025
- Published by Elsevier in Regenerative Therapy
- Vol. 29, 35-42
Open AccessClinical efficacy of invimestrocel for acute respiratory distress syndrome caused by pneumonia: Comparison with historical data using propensity score analysis
- Open Access
- 13 September 2022
- Published by S. Karger AG in Oncology
- Vol. 100 (11) , 620-632
A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer
Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still associated with renal toxicity. Because 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) is known to be a mitochondrial activator and a heme oxygenase-1 (HO-1) inducer, 5-ALA with SFC is speculated to mitigate cisplatin-induced renal inflammation. Methods: We investigated the effects of oral administration of 5-ALA with SFC for preventing cisplatin-based nephrotoxicity in patients with lung cancer and evaluated its benefits for patients who received cisplatin-based chemotherapy. The primary endpoint was the significance of the difference between the serum creatinine (sCr) levels of the patients administered 5-ALA with SFC and those given placebo after course 1 of chemotherapy. The difference in the estimated glomerular filtration rate (eGFR) between the two groups was also evaluated as the secondary endpoint. Results: The double-blind, randomized two-arm studies were conducted at 15 medical facilities in Japan; 54 male and 20 female patients with lung cancer who received cisplatin-based chemotherapy between the ages of 42 and 75 years were included in the study. The compliance rate was greater than 94% in the primary assessment and subsequent drug administration periods. All enrolled patients completed the four cycles of cisplatin-based chemotherapy with short hydration. The average level of sCr on day 22 of course 1 was 0.707 mg/dL in the group treated with 5-ALA and SFC and 0.735 mg/dL in the placebo group, respectively, and the sCr in the test group was significantly lower than that in the placebo group (p = 0.038). In addition, the eGFR was significantly higher in the SPP-003 group than in the placebo group up to day 1 of course 3 (84.66 and 75.68 mL/min/1.73 m2, respectively, p = 0.02) and kept better even after the last administration of the study drug (82.37 and 73.49 mL/min/1.73 m2, respectively, p = 0.013). Conclusions: The oral administration of 5-ALA with SFC is beneficial to patients undergoing cisplatin-based chemotherapy for lung cancer with short hydration.
- 13 September 2022
- Published by S. Karger AG in Oncology
- Vol. 100 (11) , 620-632
Open AccessA Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer
Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still associated with renal toxicity. Because 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) is known to be a mitochondrial activator and a heme oxygenase-1 (HO-1) inducer, 5-ALA with SFC is speculated to mitigate cisplatin-induced renal inflammation. Methods: We investigated the effects of oral administration of 5-ALA with SFC for preventing cisplatin-based nephrotoxicity in patients with lung cancer and evaluated its benefits for patients who received cisplatin-based chemotherapy. The primary endpoint was the significance of the difference between the serum creatinine (sCr) levels of the patients administered 5-ALA with SFC and those given placebo after course 1 of chemotherapy. The difference in the estimated glomerular filtration rate (eGFR) between the two groups was also evaluated as the secondary endpoint. Results: The double-blind, randomized two-arm studies were conducted at 15 medical facilities in Japan; 54 male and 20 female patients with lung cancer who received cisplatin-based chemotherapy between the ages of 42 and 75 years were included in the study. The compliance rate was greater than 94% in the primary assessment and subsequent drug administration periods. All enrolled patients completed the four cycles of cisplatin-based chemotherapy with short hydration. The average level of sCr on day 22 of course 1 was 0.707 mg/dL in the group treated with 5-ALA and SFC and 0.735 mg/dL in the placebo group, respectively, and the sCr in the test group was significantly lower than that in the placebo group (p = 0.038). In addition, the eGFR was significantly higher in the SPP-003 group than in the placebo group up to day 1 of course 3 (84.66 and 75.68 mL/min/1.73 m2, respectively, p = 0.02) and kept better even after the last administration of the study drug (82.37 and 73.49 mL/min/1.73 m2, respectively, p = 0.013). Conclusions: The oral administration of 5-ALA with SFC is beneficial to patients undergoing cisplatin-based chemotherapy for lung cancer with short hydration.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 17
Monocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: A retrospective cohort study
Recent studies have suggested that an increased peripheral monocyte count predicts a poor outcome in fibrosing interstitial lung disease (ILD). However, the association between an increased monocyte count and acute exacerbations (AEs) of fibrosing ILD remains to be elucidated. Our retrospective cohort study aimed to assess the impact of peripheral monocyte count on AEs of fibrosing ILD. We analyzed the electronic medical records of 122 consecutive patients with fibrosing ILD and no prior history of an AE, who were treated with anti-fibrotic agents from August 2015 to December 2018. We determined their peripheral monocyte counts at anti-fibrotic agent initiation and performed univariate and multivariate Cox regression analyses of time-to-first AE after anti-fibrotic agent initiation to assess the impact of monocyte count on AEs of fibrosing ILD. Twenty-six patients developed an AE during the follow-up period, and there was an increased monocyte count at anti-fibrotic agent initiation in these patients compared to those who did not develop an AE. There was also a significantly shorter time-to-first AE of fibrosing ILD in patients with a higher absolute monocyte count. Subgroup analyses indicated similar results regardless of the idiopathic pulmonary fibrosis diagnoses. This association was independently significant after adjusting for the severity of the fibrosing ILD. Using our results, we developed a simple scoring system consisting of two factors—monocyte count (<>380 µL−1) and ILD-gender, age, physiology score (<>4 points). Our findings suggest that the absolute monocyte count is an independent significant risk factor for AE in patients with fibrosing ILD. Our simple scoring system may be a predictor for AEs of fibrosing ILD, although further studies are needed to verify our findings.
- 1 January 2020
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 17
Open AccessMonocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: A retrospective cohort study
Recent studies have suggested that an increased peripheral monocyte count predicts a poor outcome in fibrosing interstitial lung disease (ILD). However, the association between an increased monocyte count and acute exacerbations (AEs) of fibrosing ILD remains to be elucidated. Our retrospective cohort study aimed to assess the impact of peripheral monocyte count on AEs of fibrosing ILD. We analyzed the electronic medical records of 122 consecutive patients with fibrosing ILD and no prior history of an AE, who were treated with anti-fibrotic agents from August 2015 to December 2018. We determined their peripheral monocyte counts at anti-fibrotic agent initiation and performed univariate and multivariate Cox regression analyses of time-to-first AE after anti-fibrotic agent initiation to assess the impact of monocyte count on AEs of fibrosing ILD. Twenty-six patients developed an AE during the follow-up period, and there was an increased monocyte count at anti-fibrotic agent initiation in these patients compared to those who did not develop an AE. There was also a significantly shorter time-to-first AE of fibrosing ILD in patients with a higher absolute monocyte count. Subgroup analyses indicated similar results regardless of the idiopathic pulmonary fibrosis diagnoses. This association was independently significant after adjusting for the severity of the fibrosing ILD. Using our results, we developed a simple scoring system consisting of two factors—monocyte count (<>380 µL−1) and ILD-gender, age, physiology score (<>4 points). Our findings suggest that the absolute monocyte count is an independent significant risk factor for AE in patients with fibrosing ILD. Our simple scoring system may be a predictor for AEs of fibrosing ILD, although further studies are needed to verify our findings.
- Open Access
- 3 November 2019
- Published by Wiley in Thoracic Cancer
- Vol. 10 (12) , 2259-2266
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
Background: The use of baseline tumor burden (TB) as a prognostic factor for non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) and associations between TB and other prognostic biomarkers remain unclear. In this study, we investigated the association between TB and survival in NSCLC patients treated with ICIs in comparison with other biomarkers.Methods: We retrospectively evaluated 83 NSCLC patients with ICIs administered between February 2016 and December 2018. TB was measured as the sum of the unidimensional diameters of up to five target lesions.Results: The median observation period was 14.2 months. A total of 42 patients died during the follow‐up. Univariate Cox regression analysis showed that baseline TB was associated with OS. Cox regression analysis adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS) alone or with addition of programmed cell death ligand 1 expression and treatment line showed that TB was a prognostic factor for OS. Using time‐dependent receiver operating characteristic curve analysis, the optimal TB cutoff for predicting OS was 12 cm, and patients were divided into a high TB group (n = 21) and a low TB group (n = 62). The low TB group achieved significantly longer OS than the high TB group (median OS: 18.5 months, [95% CI = 11.7‐not reached] vs. 2.3 months [95% CI = 1.3–2.9], P < 0.001).Conclusion: TB is a useful, clinically measurable prognostic factor of survival in NSCLC patients treated with ICIs.
- 3 November 2019
- Published by Wiley in Thoracic Cancer
- Vol. 10 (12) , 2259-2266
Open AccessComparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
Background: The use of baseline tumor burden (TB) as a prognostic factor for non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) and associations between TB and other prognostic biomarkers remain unclear. In this study, we investigated the association between TB and survival in NSCLC patients treated with ICIs in comparison with other biomarkers.Methods: We retrospectively evaluated 83 NSCLC patients with ICIs administered between February 2016 and December 2018. TB was measured as the sum of the unidimensional diameters of up to five target lesions.Results: The median observation period was 14.2 months. A total of 42 patients died during the follow‐up. Univariate Cox regression analysis showed that baseline TB was associated with OS. Cox regression analysis adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS) alone or with addition of programmed cell death ligand 1 expression and treatment line showed that TB was a prognostic factor for OS. Using time‐dependent receiver operating characteristic curve analysis, the optimal TB cutoff for predicting OS was 12 cm, and patients were divided into a high TB group (n = 21) and a low TB group (n = 62). The low TB group achieved significantly longer OS than the high TB group (median OS: 18.5 months, [95% CI = 11.7‐not reached] vs. 2.3 months [95% CI = 1.3–2.9], P < 0.001).Conclusion: TB is a useful, clinically measurable prognostic factor of survival in NSCLC patients treated with ICIs.
- Open Access
- 25 June 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-9
Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
Here, we present real-world data on the incidence and risk factors of acute exacerbation (AE) in patients with chronic fibrotic interstitial pneumonia (CFIP) treated with antifibrotic agents, which has been previously poorly documented. We retrospectively examined clinical characteristics, incidence and risk factors of AE in a cohort of 100 patients with CFIP (n = 75, idiopathic pulmonary fibrosis [IPF]; n = 25, other conditions), all of whom received antifibrotic agents in a real-world setting. The median follow-up was 17.4 months (interquartile range [IQR], 6.6 to 26.7 months). During the follow-up periods, 21 patients experienced AE after starting antifibrotic agents. The estimated 1-, 2-, and 3-year AE incidence rates were 11.4% (95% confidence interval [95%CI], 6.2–20.3%), 32% (95%CI, 20.7–47.4%), and 36.3% (95%CI 23.5–53.1%), respectively. Decreased baseline lung function (forced vital capacity and carbon monoxide diffusing capacity of the lung), existence of pulmonary hypertension estimated from an echocardiogram, higher Interstitial Lung Disease-Gender, Age, and Physiology (ILD-GAP) score, supplementary oxygen, and concomitant corticosteroid and proton-pump inhibitor (PPI) use upon starting the antifibrotic agent were risk factors of AE. Concomitant corticosteroid and PPI use and corticosteroid dose were risk factor of AE in a multivariate Cox regression hazard model adjusting for ILD-GAP score. AE of CFIP is more common in patients with physiologically and functionally advanced disease under antifibrotic agents. Prudent use of corticosteroids and PPIs when initiating antifibrotic agents may be recommended. Further studies are warranted.
- 25 June 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-9
Open AccessAcute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
Here, we present real-world data on the incidence and risk factors of acute exacerbation (AE) in patients with chronic fibrotic interstitial pneumonia (CFIP) treated with antifibrotic agents, which has been previously poorly documented. We retrospectively examined clinical characteristics, incidence and risk factors of AE in a cohort of 100 patients with CFIP (n = 75, idiopathic pulmonary fibrosis [IPF]; n = 25, other conditions), all of whom received antifibrotic agents in a real-world setting. The median follow-up was 17.4 months (interquartile range [IQR], 6.6 to 26.7 months). During the follow-up periods, 21 patients experienced AE after starting antifibrotic agents. The estimated 1-, 2-, and 3-year AE incidence rates were 11.4% (95% confidence interval [95%CI], 6.2–20.3%), 32% (95%CI, 20.7–47.4%), and 36.3% (95%CI 23.5–53.1%), respectively. Decreased baseline lung function (forced vital capacity and carbon monoxide diffusing capacity of the lung), existence of pulmonary hypertension estimated from an echocardiogram, higher Interstitial Lung Disease-Gender, Age, and Physiology (ILD-GAP) score, supplementary oxygen, and concomitant corticosteroid and proton-pump inhibitor (PPI) use upon starting the antifibrotic agent were risk factors of AE. Concomitant corticosteroid and PPI use and corticosteroid dose were risk factor of AE in a multivariate Cox regression hazard model adjusting for ILD-GAP score. AE of CFIP is more common in patients with physiologically and functionally advanced disease under antifibrotic agents. Prudent use of corticosteroids and PPIs when initiating antifibrotic agents may be recommended. Further studies are warranted.